| Nancy A Dimartino, MD | |
|
1345 Unity Pl, Ste 135, Lafayette, IN 47905-5762 | |
| (765) 446-5050 | |
| (765) 446-5119 |
| Full Name | Nancy A Dimartino |
|---|---|
| Gender | Female |
| Speciality | Hematology/oncology |
| Experience | 45 Years |
| Location | 1345 Unity Pl, Lafayette, Indiana |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1780687152 | NPI | - | NPPES |
| 200106510A | Medicaid | IN | |
| 200106510 | Medicaid | IN |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 01045452A (Indiana) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Franciscan Health Lafayette | Lafayette, IN | Hospital |
| Indiana University Health White Memorial Hospital | Monticello, IN | Hospital |
| Indiana University Health Arnett Hospital | Lafayette, IN | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Unity Healthcare Llc | 0244123362 | 76 |
News Archive
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
Pieris AG, a bio-pharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma.
Addicts crave drugs and suffer relapse not just because of the alluring high of drugs, but also because they are compelled by the powerful, haunting memory associations with the environment surrounding their drug taking. Thus, treatments that could eliminate those memory associations could prove effective in treating addiction, researchers believe.
Cardiac researchers at the University of Pennsylvania have received a $2.1 million grant from the National Institutes of Health (NIH) to pioneer studies in cardiovascular disease management and participate in a novel collaboration network to develop and implement research in this critically important field.
A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.
› Verified 6 days ago
| Entity Name | Unity Healthcare Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1619929098 PECOS PAC ID: 0244123362 Enrollment ID: O20040203001083 |
News Archive
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
Pieris AG, a bio-pharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma.
Addicts crave drugs and suffer relapse not just because of the alluring high of drugs, but also because they are compelled by the powerful, haunting memory associations with the environment surrounding their drug taking. Thus, treatments that could eliminate those memory associations could prove effective in treating addiction, researchers believe.
Cardiac researchers at the University of Pennsylvania have received a $2.1 million grant from the National Institutes of Health (NIH) to pioneer studies in cardiovascular disease management and participate in a novel collaboration network to develop and implement research in this critically important field.
A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Nancy A Dimartino, MD Po Box 4699, Lafayette, IN 47903-4699 Ph: (765) 449-2732 | Nancy A Dimartino, MD 1345 Unity Pl, Ste 135, Lafayette, IN 47905-5762 Ph: (765) 446-5050 |
News Archive
AstraZeneca today announced that on March 7, 2012, the Food and Drug Administration denied Citizen Petitions requesting that the FDA withhold finally approving any generic quetiapine product with labeling that omits certain hyperglycemia warning language that the FDA required AstraZeneca to include in the labeling for SEROQUEL (quetiapine fumarate) tablets and SEROQUEL XR (quetiapine fumarate) extended-release tablets.
Pieris AG, a bio-pharmaceutical company developing Anticalins, a novel class of targeted human protein therapeutics, today announced significant progress in validating novel, effective products for the potential treatment of asthma.
Addicts crave drugs and suffer relapse not just because of the alluring high of drugs, but also because they are compelled by the powerful, haunting memory associations with the environment surrounding their drug taking. Thus, treatments that could eliminate those memory associations could prove effective in treating addiction, researchers believe.
Cardiac researchers at the University of Pennsylvania have received a $2.1 million grant from the National Institutes of Health (NIH) to pioneer studies in cardiovascular disease management and participate in a novel collaboration network to develop and implement research in this critically important field.
A study by scientists in Manchester has shown how melanoma drugs can cause the cancer to progress once a patient has stopped responding to treatment.
› Verified 6 days ago
Michelle B Herberts, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2600 Greenbush St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-448-8564 | |
Dr. Carlos Salazar Carcamo, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2600 Greenbush St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-583-2444 | |
Maria L Srour, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 5165 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8000 Fax: 765-448-7631 | |
Steven Rudolf Steinhubl, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 5177 Mccarty Ln, Lafayette, IN 47905 Phone: 765-448-8000 Fax: 765-838-4333 | |
Michael Leo Hogan, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3900 St Francis Way Ste 200, Lafayette, IN 47905 Phone: 765-775-2800 Fax: 765-775-2831 | |
Carlos A Gambirazio, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2600 Greenbush St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-448-7624 | |
Dr. Christopher Patrick Kaup, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2600 Ferry St, Lafayette, IN 47904 Phone: 765-448-8000 Fax: 765-838-4698 |